Get started
Author

Lars Mouritsen

Observed names: L. Mouritsen, Lars Mouritsen (14941479)
ORCID: 0009-0001-7401-0303
Observed ORCID: 0009-0001-7401-0303
OpenAlex ID: A5041589484
Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer
2020 · Josephine A. Taverna, Chia-Nung Hung, et al. · Cancer Research · 64
Acute Endogenous Endophthalmitis Due toBartonella henselae
2001 · Debra A. Goldstein, Lars Mouritsen, et al. · Clinical Infectious Diseases · 26
Comparison of three commercially available enzyme immunoassays for the screening of autoantibodies to extractable nuclear antigens
1995 · Troy D. Jaskowski, Carl Schroder, et al. · Journal of Clinical Laboratory Analysis · 23
AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2023 · R. Leo Sakemura, Mehrdad Hefazi, et al. · Cancer Immunology Research · 13
PDF
A phase Ia/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumours
2019 · J. Sarantopoulos, G. Fotopoulos, et al. · Annals of Oncology · 11
A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-1287 administered daily to patients with advanced solid tumors.
2020 · Ben George, Donald A. Richards, et al. · Journal of Clinical Oncology · 9
A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654 administered daily for 28 days to patients with advanced solid tumors.
2020 · Ignacio Garrido-Laguna, Patrick Michael Dillon, et al. · Journal of Clinical Oncology · 7
A phase 1a / 1b first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-0903, a potent inhibitor of AXL kinase, administered daily for 21 days to patients with advanced solid tumors.
2018 · John Sarantopoulos, Muhammad Shaalan Beg, et al. · Journal of Clinical Oncology · 5
Abstract 2006: Targeting AXL kinase with TP-0903 successfully reverses the mesenchymal phenotype and extends survival in preclinical models of advanced ovarian cancer
2019 · Nozomi Tomimatsu, Ken Fujimura, et al. · Cancer Research · 3
Abstract 2197: The AXL kinase inhibitor, TP-0903, demonstrates efficacy in preclinical models of colorectal cancer independent of KRAS mutation status
2019 · Ryan Mangelson, Peter Peterson, et al. · Cancer Research · 3
Axl-RTK Inhibition Modulates T Cell Functions and Synergizes with Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies
2019 · Reona Sakemura, Nan Yang, et al. · Transplantation and Cellular Therapy · 3
PDF
Axl-RTK Inhibition Modulates Monocyte Immune Response to Enhance the Anti-Tumor Effects of CD19 Redirected Chimeric Antigen Receptor T Cells in Preclinical Models
2020 · Reona Sakemura, Michelle J. Cox, et al. · Blood · 2
Axl-RTK Inhibition Modulates T Cell Functions and Synergizes with Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies
2018 · Reona Sakemura, Nan Yang, et al. · Blood · 2
Abstract B29: AXL Inhibitor TP-0903 attenuates TGFβ-Hippo signaling in lung adenocarcinoma cells
2020 · Josephine A. Taverna, Chia-Nung Hung, et al. · Molecular Cancer Research · 1
Abstract 2193: AXL inhibitor TP-0903 attenuates AXL-TGFbeta Hippo signaling axis in lung adenocarcinoma cells
2019 · Josephine Amalia Taverna, Chia-Nung Hung, et al. · Cancer Research · 1
Supplementary Table S2 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025 · R. Leo Sakemura, Mehrdad Hefazi, et al.
Supplementary Figure Legends from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025 · R. Leo Sakemura, Mehrdad Hefazi, et al.
Supplementary Figures from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025 · R. Leo Sakemura, Mehrdad Hefazi, et al.
Supplementary Table S1 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025 · R. Leo Sakemura, Mehrdad Hefazi, et al.
Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024 · R. Leo Sakemura, Mehrdad Hefazi, et al.
Supplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024 · R. Leo Sakemura, Mehrdad Hefazi, et al.
Supplementary Figures from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024 · R. Leo Sakemura, Mehrdad Hefazi, et al.
Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024 · R. Leo Sakemura, Mehrdad Hefazi, et al.
Data from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024 · R. Leo Sakemura, Mehrdad Hefazi, et al.
Supplementary Figure Legends from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024 · R. Leo Sakemura, Mehrdad Hefazi, et al.
Works count: 53
Citation count: 173
H-index: 7
I10-index: 5
Year
Topic
Type